ARCT:NASDAQ
Arcturus Therapeutics Holdings Inc
$10.42
arrow_upward
+0.77%(+0.080) 1D
$10.42
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 19, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ARCT...
Open
$10.47
High
$10.79
Low
$10.29
Mkt. cap
296.17M
Avg. vol.
758.06K
Volume
635.66K
52-wk high
$24.14
52-wk low
$5.50
EPS
-$3.31
Beta
2.48
Shares outstanding
28.42M
No. of employees
109
Open
$10.47
High
$10.79
Low
$10.29
Mkt. cap
296.17M
Avg. vol.
758.06K
Volume
635.66K
52-wk high
$24.14
52-wk low
$5.50
EPS
-$3.31
Beta
2.48
Shares outstanding
28.42M
No. of employees
109
News stories
From web sources and news partners
investingLive
·
42 minutes ago
Nasdaq and S&P rebounds; Dow slips
TradingView
·
39 minutes ago
The Dow Jones Index Closes 0.07% Lower
Traders Union
·
35 minutes ago
Sherwin-Williams rebound signals improving momentum for Dow stock
Investing.com
·
38 minutes ago
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.07%
Profile
Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA.
The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. Vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025. Wikipedia
About Arcturus Therapeutics Holdings Inc